Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CEMI

Chembio Diagnostics (CEMI) Stock Price, News & Analysis

Chembio Diagnostics logo

About Chembio Diagnostics Stock (NASDAQ:CEMI)

Key Stats

Today's Range
$0.45
$0.46
50-Day Range
$0.33
$0.46
52-Week Range
$0.19
$1.24
Volume
351,642 shs
Average Volume
661,416 shs
Market Capitalization
$16.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Stock News Headlines

Quest Diagnostics Inc DGX
Tesla Execs are Freaking Out
It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.
See More Headlines

CEMI Stock Analysis - Frequently Asked Questions

Chembio Diagnostics, Inc. (NASDAQ:CEMI) released its earnings results on Thursday, November, 4th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.05. The firm earned $12.06 million during the quarter. Chembio Diagnostics had a negative net margin of 47.03% and a negative trailing twelve-month return on equity of 113.57%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), NovoCure (NVCR), BlackRock Capital Investment (BKCC), Viper Energy (VNOM) and Summit Midstream Partners (SMLP).

Company Calendar

Last Earnings
11/04/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CEMI
Employees
337
Year Founded
N/A

Profitability

Net Income
$-23,290,000.00
Pretax Margin
-46.96%

Debt

Sales & Book Value

Annual Sales
$48.34 million
Book Value
$0.48 per share

Miscellaneous

Free Float
35,514,000
Market Cap
$16.71 million
Optionable
Not Optionable
Beta
1.85

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CEMI) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners